In some cases, it may be appropriate to give EBRT in the adjuvant setting if there is confirmed or suspected microscopic residual disease that is confirmed or suspected to be refractory to RAI
Ongoing research is exploring these issues and looking at combining GLP-1 agonists and dual agonists with other treatments for more comprehensive weight management[2][4]
- **Liraglutide (Saxenda)** *Disclaimer* All antiobesity and Weight loss drugs come with their side effects and contraindications
The patients preference, comfort and ease with technology, willingness to engage with the device, caregiver support, interacting medications, and insurance coverage, along with device affordability, are important factors in determining which CGM is appropriate
Laser energy then liquefies the fat for convenient and comfortable extraction
You need a comprehensive approach to heal your relationship with food, whether you choose to include GLP-1 medication or not